POST-POLYCYTHEMIA VERA MYELOFIBROSIS (PPV-MF)
Clinical trials for POST-POLYCYTHEMIA VERA MYELOFIBROSIS (PPV-MF) explained in plain language.
Never miss a new study
Get alerted when new POST-POLYCYTHEMIA VERA MYELOFIBROSIS (PPV-MF) trials appear
Sign up with your email to follow new studies for POST-POLYCYTHEMIA VERA MYELOFIBROSIS (PPV-MF), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo therapy aims to shrink enlarged spleens in myelofibrosis patients
Disease control Recruiting nowThis phase 3 trial tests whether adding pelabresib to the standard drug ruxolitinib works better than ruxolitinib alone for people with myelofibrosis, a bone marrow cancer that often causes an enlarged spleen and severe symptoms. About 460 adults who have not taken JAK inhibitors…
Matched conditions: POST-POLYCYTHEMIA VERA MYELOFIBROSIS (PPV-MF)
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated May 04, 2026 16:23 UTC
-
New registry aims to unlock secrets of rare blood cancers
Knowledge-focused Recruiting nowThis study follows 5,000 adults with myeloproliferative neoplasms (MPNs) — rare blood cancers — to understand how symptoms change and how the disease progresses over years. Participants share their health records, insurance data, and regular surveys about how they feel. No new tr…
Matched conditions: POST-POLYCYTHEMIA VERA MYELOFIBROSIS (PPV-MF)
Sponsor: MPN Research Foundation • Aim: Knowledge-focused
Last updated May 04, 2026 16:17 UTC